NCT07319078 Pain in Pediatric Patients - Internet Interventions for Disorders of Gut-brain Interaction
| NCT ID | NCT07319078 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Karolinska Institutet |
| Condition | Irritable Bowel Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-12-01 |
| Primary Completion | 2030-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2025-12-01 with a primary completion date of 2030-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Many children and adolescents often experience long-lasting stomach pain. In many cases, this is due to disorders of gut-brain interaction (DGBI), such as irritable bowel syndrome (IBS), functional abdominal pain, and functional dyspepsia. These conditions are caused by disrupted communication between the brain and the gut. They are linked to significant suffering, reduced quality of life, and higher school absenteeism. Psychological treatments such as cognitive behavioral therapy (CBT) have shown good effect, but waiting times within healthcare are often long. Therefore, there is a need for more accessible and cost-effective treatment alternatives. The goal of this clinical trial is to explore whether gut-directed hypnotherapy, already used successfully in the Netherlands, can be implemented as a new treatment option in Swedish healthcare. In addition, the study will compare gut-directed hypnotherapy with internet-based CBT (iCBT) to learn which digital treatment works best for children and adolescents with DGBI. Participants will: Be children or adolescents between 8 and 17 years old. First take part in a 4-week online education program called the "gut-school," which explains the stomach, the brain, and how symptoms can be managed. If symptoms remain after the gut-school, be randomly assigned to one of two digital treatments: iCBT (internet-based cognitive behavioral therapy). 10 week long. Gut-directed hypnotherapy, delivered as audio recordings to be used at home. 12 week long. Answer online survey questions before, during, and after treatment so researchers can follow their progress. These two treatments have never been directly compared. By comparing them, researchers hope to learn not only which treatment works best overall, but also which treatment is most suitable for different participants. The long-term aim is to make gut-directed hypnotherapy, already successful in the Netherlands, available as a treatment option in Sweden.
Eligibility Criteria
Inclusion Criteria: * Age 8-17 years * Basic somatic work-up completed (CRP/ESR, TGA, complete blood count, fecal calprotectin) * Confirmed DGBI diagnosis: IBS, functional abdominal pain, or functional dyspepsia (according to Rome IV criteria) * Any constipation must be treated according to current clinical guidelines, with stable laxative dosing for at least one month prior to referral * In cases of celiac disease, the participant must have followed a gluten-free diet for at least six months and TGA values must have normalized * For participants with a neuropsychiatric diagnosis treated with medication, at least two months must have passed since the last dose adjustment * At least one parent and the child/adolescent must be fluent in Swedish and willing to participate in both the educational program and treatment (regardless of randomization outcome), complete homework assignments, and respond to questionnaires Exclusion Criteria: * Other organic disease that better explains the gastrointestinal symptoms * At referral assessment, psychiatric symptoms or psychosocial problems - such as severe bullying, high school absenteeism, or difficult family circumstances - are judged to be more prominent than the gastrointestinal problems and require more extensive, multiprofessional care than what the study can offer * Participants who have already completed gut-directed hypnotherapy or CBT
Contact & Investigator
Ola Olén, Professor
STUDY CHAIR
Karolinska Institutet
Frequently Asked Questions
Who can join the NCT07319078 clinical trial?
This trial is open to participants of all sexes, aged 8 Years or older, up to 17 Years, studying Irritable Bowel Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07319078 currently recruiting?
Yes, NCT07319078 is actively recruiting participants. Contact the research team at tea.soini@ki.se for enrollment information.
Where is the NCT07319078 trial being conducted?
This trial is being conducted at Stockholm, Sweden.
Who is sponsoring the NCT07319078 clinical trial?
NCT07319078 is sponsored by Karolinska Institutet. The principal investigator is Ola Olén, Professor at Karolinska Institutet. The trial plans to enroll 200 participants.